Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

26 results about "Shiga toxin" patented technology

Shiga toxins are a family of related toxins with two major groups, Stx1 and Stx2, expressed by genes considered to be part of the genome of lambdoid prophages. The toxins are named after Kiyoshi Shiga, who first described the bacterial origin of dysentery caused by Shigella dysenteriae. Shiga-like toxin (SLT) is a historical term for similar or identical toxins produced by Escherichia coli. The most common sources for Shiga toxin are the bacteria S. dysenteriae and some serotypes of Escherichia coli (STEC), which includes serotypes O157:H7, and O104:H4.

Methods and compositions for detecting virulent and avirulent Escherichia coli strains

Disclosed herein are methods for detecting virulent Shiga toxin-producing E. coli (STEC) strains O26, O103, O121, and O111 in a biological sample comprising the steps of: (i) enriching the bacterial concentration of the biological sample to result in an enriched sample; (ii) isolating DNA from said enriched biological sample; and (iii) detecting virulent strain in said isolated DNA sample via real-time PCR and a melt curve assay. Also disclosed are primers for said assay, as well as kits comprising said primers.
Owner:FLORIDA STATE UNIV RES FOUND INC

Multiplex panel for detecting gastrointestinal bacterial nucleic acids

PCT designated stage expiredWO2025024517A1Microbiological testing/measurementAntibody ingredientsShigella spCampylobacter sp
Described herein are compositions, methods, and kits for detecting diarrhea causing pathogens from patient, food, or environmental samples. One embodiment described herein is primer pairs and probes for multiplex polymerase chain reaction (PCR) based assays for the detection of diarrhea causing pathogens, such as Campylobacter sp., Salmonella sp., Shigella sp. / Enteroinvasive Escherichia coli (EIEC), Escherichia coli stx1 / Shiga toxin A or Escherichia coli stx2 / Shiga toxin B. Other embodiments include methods and kits for detecting diarrhea causing pathogens.
Owner:LIFE TECHNOLOGIES CORP

An enrichment device for shiga toxin-producing escherichia coli

This utility model relates to the field of microbial detection technology, and in particular to an enrichment device for Shiga toxin-producing Escherichia coli. The technical solution includes an enrichment container body, a sealing cap at the top for sealing, a shock-absorbing pad at the bottom for reducing amplitude, and a stirring structure at the top of the sealing cap for mixing the sample solution. The stirring structure includes a motor for driving the mixture, and a rotating shaft fixedly mounted at the output end of the motor. The rotating shaft passes through the sealing cap and has multiple stirring blades spirally distributed on its exterior. This utility model, through the arrangement of the motor, stirring blades, and connecting rod, allows the motor to be activated after the sample solution and enrichment solution are added. The motor drives the rotating shaft, which in turn rotates the multiple stirring blades. The stirring blades stir the two liquids, enabling a more uniform mixing of the sample solution and enrichment solution, avoiding localized excessively high or low concentrations, and improving the uniformity and efficiency of the enrichment.
Owner:FOOD INSPECTION CENT OF CIQ SHENZHEN

Application of Pladienolide B in the preparation of drugs against Shiga toxin

The present invention discloses the use of Pladienolide B in the preparation of drugs against Shiga toxin. The present invention also discloses an anti-Shiga toxin pharmaceutical composition and an anti-Shiga toxin pharmaceutical preparation comprising the compound Pladienolide B. The present invention proves through experiments that the compound Pladienolide B can be used in the preparation of drugs against Shiga toxin, provides a new strategy for the research and development of drugs against Shiga toxin, and has broad application prospects.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Product for detecting food-borne pathogenic bacteria by time-of-flight mass spectrometry

The invention provides a product for detecting eight food-borne pathogenic bacteria by time-of-flight mass spectrometry, which comprises a specific primer group of multiple PCR (Polymerase Chain Reaction) of the eight food-borne pathogenic bacteria, wherein the food-borne pathogenic bacteria comprise intestinal aggregation Escherichia coli, intestinal hemorrhagic Escherichia coli, intestinal invasive Escherichia coli, intestinal pathogenic Escherichia coli, Shiga toxin producing Escherichia coli, enterotoxin producing Escherichia coli, listeria monocytogenes and salmonella typhimurium. The detection vehicle product is used for carrying out multiple PCR amplification on pathogen DNA, and the size of a fragment of the multiple PCR product is detected through MALDI-TOF MS (matrix-assisted laser desorption / ionization time of flight mass spectrometry). According to the method, multiple PCR and MALDI-TOF MS are combined to be used for identifying clinical pathogenic microorganisms, and the method is rapid, simple, convenient, easy to observe, visual and high in accuracy.
Owner:二连海关技术中心 +1

Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector

The present disclosure relates to PD-L1-binding molecules comprising a Shiga toxin effector region, a PD-L1-binding region, and a T cell epitope, and pharmaceutical compositions thereof. The PD-L1 binding molecules and pharmaceutical compositions thereof have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and / or immune cells), for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutics for treating or slowing the progression of cancer (e.g., non-small cell lung cancer or squamous cell carcinoma of the head and neck). The present disclosure also relates to clinical methods for use of the disclosed PD-L1 binding molecules for treating a subject in need thereof.
Owner:MOLECULAR TEMPLATES INC

Specific primer for detecting swine edema disease and application thereof

The invention discloses a specific primer pair for detecting a swine edema disease. The specific primer pair comprises a forward primer Stx2eF and a reverse primer Stx2eR, wherein the nucleotide sequence of the forward primer Stx2eF is as shown in SEQ ID NO: 1, and the nucleotide sequence of the reverse primer Stx2eR is as shown in SEQ ID NO: 2. Data show that the detection result of a sample inoculated with Shiga toxin-producing escherichia coli containing the Stx2e gene by using the primer pair disclosed by the invention is highly consistent with the actual infection degree, and the pathogenic bacterium load can be dynamically quantified through a standard curve. By means of the advantage, early warning of the pig edema disease can be achieved, and a key time window is provided for early prevention and control.
Owner:GUANGXI UNIV

Enzyme substrate for the detection of shiga toxin

PCT designated stage expiredWO2024231269A1Microbiological testing/measurementMaterial analysisRicinus sanguineusNucleotide
The invention relates to an oligonucleotide comprising a) a nucleotide sequence of a sarcin-ricin loop (SRL) of a eukaryotic / mammalian 60S ribosomal sub-unit, wherein the SRL nucleotide sequence comprises at least one adenine, and b) at least one cleavage-dependent label, wherein the oligonucleotide is single-stranded. Preferably, the oligonucleotide forms at least one loop or stem-loop structure. In a further aspect, the invention relates to a method for detecting an active shiga toxin in a sample, said method comprising the steps of: a) providing at least one oligonucleotide according to the invention, b) providing a sample to be tested for shiga toxin, c) incubating the sample with the at least one single-stranded oligonucleotide, and d) detecting a signal of a label, wherein a signal is indicative of the presence of a shiga toxin in the sample. The invention additionally comprises a kit comprising at least one oligonucleotide according to the invention.
Owner:ROBERT KOCH INSTITUTE +1

Enzyme substrates for detecting shiga toxins

The present invention relates to an oligonucleotide comprising: a) a nucleotide sequence of a broom-kojin-ricin loop (SRL) of a eukaryotic / mammalian 60S ribosomal subunit wherein the SRL nucleotide sequence comprises at least one adenine; and b) at least one cut-dependent marker; wherein the oligonucleotide is a single strand. Preferably, the oligonucleotides form at least one loop structure or stem-loop structure. In another aspect, the invention relates to a method of detecting active shiga toxin in a sample, the method comprising the steps of: a) providing at least one oligonucleotide according to the invention; b) providing a sample of shiga toxin to be detected; c) incubating the sample with at least one single-stranded oligonucleotide; and d) detecting a labeled signal, wherein the signal indicates the presence of Shiga toxin in the sample. The invention additionally comprises a kit comprising at least one oligonucleotide according to the invention.
Owner:ROBERT KOCH INSTITUTE +1

A sampling device for detection of shiga toxin-producing escherichia coli

ActiveCN224456282UEscherichia coliDisease
The utility model relates to sample sampling device technical field especially, it is used for the sampling device for shiga toxin producing escherichia coli detection. Its technical scheme includes sampling cylinder and rotates and installs the rotating sampling assembly in sampling cylinder, the bottom of rotating sampling assembly is provided with the lower cover of screw thread rotation and is installed in the bottom of sampling cylinder and is closed, rotating sampling assembly includes the outer sleeve rod and sets up in the inner sleeve rod of outer sleeve rod, the bottom end of inner sleeve rod is provided with the sampling clamp for shiga toxin producing escherichia coli sampling, the sampling clamp includes the fixed rod of rotation and is installed below sampling clamp, the bottom end fixedly connected with sampling spoon of fixed rod. The utility model is accurate in sampling, avoids to contaminate, realizes the accurate, safe, convenient sampling of all kinds of samples, improves the reliability and efficiency of shiga toxin producing escherichia coli detection, provides the powerful technical support for food safety, environmental protection and disease diagnosis etc.
Owner:FOOD INSPECTION CENT OF CIQ SHENZHEN

Application of BRD4780 serving as anti-shiga toxin protective agent and related products of BRD4780

The invention discloses application of a compound BRD4780 as an anti-shiga toxin protective agent and related products thereof, and provides an anti-shiga toxin pharmaceutical composition and a pharmaceutical preparation, it is found for the first time that the compound BRD4780 can be used as the effective anti-shiga toxin protective agent, the BRD4780 can effectively inhibit the toxicity of shiga toxin I and shiga toxin II, and the compound BRD4780 can effectively inhibit the toxicity of shiga toxin I and shiga toxin II. The BRD4780 can be applied to preparation of anti-shiga toxin drugs, an effective candidate drug is provided for prevention, treatment, alleviation or improvement of shiga toxin poisoning related diseases or symptoms, and reference is provided for new application clinical research of the BRD4780 drug at the same time.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Darpin-containing compositions and methods thereof

The present disclosure provides compositions comprising a designed ankyrin repeat protein (DARPin) for use in treating Shiga toxin (Stx)-producing Escherichia coli (STEC) and related diseases, including hemolytic uremic syndrome (HUS). The high thermostability and high microbial expression yield make DARPin an attractive alternative to antibody therapeutics. The present disclosure provides monomer proteins, dimer proteins, and trimer proteins, as well as pharmaceutical compositions and methods utilizing the same.
Owner:TEXAS A&M UNIVERSITY

Shiga toxin A subunit effector polypeptides, Shiga toxin effector scaffolds and cell targeting molecules for site-specific conjugation

The present invention provides polypeptides, scaffolds and cell targeting molecules derived from Shiga toxin A subunits, which contain amino acid substitutions that provide the molecule with site-specific positions (and typically unique amino acid residues in the molecule) for attachment to other molecules while retaining one or more Shiga toxin functions, such as, for example, effective intracellular delivery and / or potent cytotoxicity. The present invention also provides cell targeting molecules and / or components thereof, which contain site-specific positions for attachment to other molecules, such as, for example, agents that change the properties of the cell targeting molecule or cargo for delivery. Certain molecules comprising the polypeptides of the present invention exhibit reduced immunogenicity and / or are well tolerated by mammals. The cell targeting molecules of the present invention and compositions thereof have, for example, the following uses: for selective delivery of cargo to cells expressing the target, and as diagnostic and / or therapeutic molecules for treating a variety of diseases, disorders and conditions, including genetic disorders, genetic susceptibility, infection, cancer, tumor, growth abnormality and / or immune disorders.
Owner:MOLECULAR TEMPLATES INC

Method for detecting food-borne pathogenic bacteria by time-of-flight mass spectrometry

The invention provides a method for detecting eight food-borne pathogenic bacteria by a time-of-flight mass spectrometry. A primer group comprises a specific primer pair combination of multiple PCR (Polymerase Chain Reaction) of the eight food-borne pathogenic bacteria, wherein the food-borne pathogenic bacteria comprise intestinal aggregation Escherichia coli, intestinal hemorrhagic Escherichia coli, intestinal invasive Escherichia coli, intestinal pathogenic Escherichia coli, Shiga toxin producing Escherichia coli, enterotoxin producing Escherichia coli, listeria monocytogenes and salmonella typhimurium. According to the method, a specific primer is used for performing multiple PCR amplification on pathogen DNA, and the size of a fragment of a multiple PCR product is detected through MALDI-TOF MS. According to the method, multiple PCR and MALDI-TOF MS are combined to be used for identifying clinical pathogenic microorganisms, and the method is rapid, simple, convenient, easy to observe, visual and high in accuracy.
Owner:二连海关技术中心 +1

Multiplex detection combination for detection of gastrointestinal bacterial nucleic acids

Described herein are compositions, methods, and kits for detecting diarrhea-causing pathogens from a patient, food, or environmental sample. One embodiment described herein is a primer pair and probe for a multiplex polymerase chain reaction (PCR)-based assay for the detection of diarrhea-causing pathogens, such as Campylobacter spp., Salmonella spp., Shigella spp. / Enteroinvasive Escherichia coli (EIEC), Escherichia coli stx1 / Shiga toxin A, or Escherichia coli stx2 / Shiga toxin B. Other embodiments include methods and kits for detecting diarrhea-causing pathogens.
Owner:LIFE TECHNOLOGIES CORP

Immunogenic formulation that induces protection against shiga toxin-producing Escherichia coli (STEC)

Disclosed is an immunogenic formulation that induces protection against Shiga Toxin-Producing Escherichia coli (STEC), the formulation comprising: one or more chimeric proteins derived wholly or in part from OmpT and Hes proteins of STEC; and at least one physiologically or pharmaceutically acceptable excipient, carrier and / or diluent.
Owner:UNIVERSITY OF CHILE

Use of brd4780 as a protective agent against shiga toxin and related products

The application discloses use of a compound BRD4780 as an anti-Shiga toxin protective agent and related products, and provides an anti-Shiga toxin pharmaceutical composition and a pharmaceutical preparation. The application first discovers that the compound BRD4780 can be used as an effective anti-Shiga toxin protective agent, and BRD4780 can effectively inhibit Shiga toxin I and Shiga toxin II toxicity, and can be used in preparation of an anti-Shiga toxin drug. The application provides an effective candidate drug for prevention, treatment, alleviation or improvement of Shiga toxin poisoning related diseases or conditions, and also provides a reference for new application clinical research of the drug BRD4780.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof

A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.
Owner:UNIV PARIS CITE +6

De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals

The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and / or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from Shiga toxins. The Shiga toxin effector polypeptides of the present invention have uses as components of therapeutics, diagnostics, and immunization materials. The cytotoxic proteins of the present invention have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. The proteins of the present invention also have uses for detecting specific cell types, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as, e.g., cancers, immune disorders, and microbial infections.
Owner:MOLECULAR TEMPLATES INC

Immunogenic fusion proteins against coronavirus

Immunogenic fusion proteins against coronavirus. A fusion protein is disclosed, which comprises a CD40-binding domain; an antigen of SARS-CoV2; a translocation domain located between the CD40-binding domain and the antigen, and a furin and / or cathepsin L cleavage site located between the CD40-binding domain and the translocation domain. In one embodiment, the translocation domain is a Shiga toxin (Stx) translocation peptide, and the antigen is located at the N-terminal of the fusion protein. In another embodiment, the translocation domain is a Pseudomonas Exotoxin A (PE) translocation peptide, and the CD40-binding domain is located at the N-terminal of the fusion protein. Also disclosed are pharmaceutical compositions, expression vectors and use of the fusion proteins of the invention for eliciting an antigen-specific cell-mediated immune response, and / or for reducing, inhibiting, treating and / or ameliorating symptoms caused by SARS-CoV2 infection in a subject in need thereof.
Owner:NAVICURE BIOPHARMACEUTICALS LTD

Formulation of a lytic bacteriophage cocktail for biocontrol of shiga toxin-producing escherichia coli strains

PCT designated stage expiredWO2025106846A1BiocideDisinfectantsEscherichia coliBacteriophage
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Selective enrichment culture medium for shiga toxin-producing Escherichia coli and application of selective enrichment culture medium

The invention discloses a selective enrichment culture medium for shiga toxin-producing Escherichia coli and application of the selective enrichment culture medium. The culture medium comprises the following components in parts by mass: 18-19 parts of casein tryptone, 3-4 parts of succinic acid, 4.5-5.5 parts of sodium chloride, 3.5-4.5 parts of dipotassium phosphate, 1-2 parts of monopotassium phosphate, 3-4 parts of glucose, 0.000045-16 parts of a selective antibacterial component and 1000 parts of distilled water, the selective antibacterial component is one or a combination of more of magnesium sulfate heptahydrate, nisin and cefixime, and the pH value of the culture medium is 7.0-7.4. The culture medium provided by the invention can reduce the inhibition of selective components on shiga toxin-producing Escherichia coli, improve the inhibition on infectious microbes, shorten the culture time and improve the culture efficiency.
Owner:BEIJING YITAI BIOTECH CO LTD

A shiga toxin-producing escherichia coli enrichment culture device

ActiveCN224280262UEnsure quality and efficiencyEnsure cultivation efficiencyBioreactor/fermenter combinationsBiological substance pretreatmentsEscherichia coliMicroorganism
This utility model relates to the field of microbial detection equipment technology, and in particular to a Shiga toxin-producing Escherichia coli enrichment culture device. The technical solution includes a culture tank body, with a sealing top cover on the top of the culture tank body. The neck of the culture tank body has two arc-shaped plates for fixation, and an alarm structure for temperature loss alarm is fixed to one side of the arc-shaped plate. This utility model utilizes a temperature sensor, a central control module, an electric push rod, and a buzzer. The temperature sensor transmits the real-time temperature to the central control module, which compares the real-time temperature with a preset temperature. If the temperature is higher or lower than the preset temperature, the electric push rod is activated to compress the guide plate, energizing the buzzer and emitting a buzzing sound. This allows relevant personnel to be immediately aware of abnormal temperature inside the culture tank and take timely measures to ensure the cultivation quality and efficiency of the equipment.
Owner:FOOD INSPECTION CENT OF CIQ SHENZHEN

CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors

The instant invention provides binding proteins (“CD38-binding proteins”) which each comprise (1) a CD38-binding region for cell-targeting and (2) a Shiga toxin A Subunit effector polypeptide (“Shiga toxin effector polypeptide”). The Shiga toxin effector polypeptide components of the CD38-binding proteins may comprise a combination of mutations relative to a wild-type Shiga toxin sequence providing (1) de-immunization and / or (2) a reduction in protease sensitivity; wherein each Shiga toxin effector polypeptide retains one or more Shiga toxin function, such as, e.g., stimulating cellular internalization, directing intracellular routing, catalytic activity, and / or potent cytotoxicity. The CD38-binding proteins may have one or multiple uses, e.g., the selective killing of a specific CD38-expressing cell-type; and more generally, for the diagnosis and treatment of cancers and disorders involving CD38-expressing cells, e.g., in CD38-positive hematopoietic cancers such as multiple myeloma.
Owner:MILLENNIUM PHARMACEUTICALS INC +1